By Sean Moloughney, Editor12.09.22
Denmark-based biotech solutions company Novozymes, which aims to preserve the planet’s resources and help build better lives through biology, has debuted its B2B human health growth platform, Novozymes OneHealth, in the U.S.
The company works with partners to create unique products with validated, targeted modes of action. Each offering addresses clear and profound consumer health challenges related to modern lifestyles, like stress, brain health, immune function, and more.
All Novozymes OneHealth products are supported by clinical studies and intellectual property protection, he added. “It is in in our DNA to have proven, clinical su
The company works with partners to create unique products with validated, targeted modes of action. Each offering addresses clear and profound consumer health challenges related to modern lifestyles, like stress, brain health, immune function, and more.
‘One-in-a-Trillion’ Microbial Solutions
Novozymes has a long history of expertise with enzymes and microbes. “We have a bank of millions of enzymes,” noted Alexander Lommer Broe, global brand manager, Novozymes OneHealth. “We want to find what we call the needle in the haystack, the ‘one-in-a-trillion solution’; that one product that helps a specific challenge.”All Novozymes OneHealth products are supported by clinical studies and intellectual property protection, he added. “It is in in our DNA to have proven, clinical su
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
